Nature Communications:日本破解特应性皮炎致痒机理,为药物开发带来契机

2017-02-16 佚名 科技部

特应性皮炎是一种过敏反应,起因是由于身体对入侵异物产生过度反应。7-15%的日本人患有这种“国民病”,由于长期的瘙痒而影响生活质量。根据近年的研究,发现其原因是体内产生了大量的致痒分子IL-31,但具体的机理一直不清楚。



特应性皮炎是一种过敏反应,起因是由于身体对入侵异物产生过度反应。7-15%的日本人患有这种“国民病”,由于长期的瘙痒而影响生活质量。根据近年的研究,发现其原因是体内产生了大量的致痒分子IL-31,但具体的机理一直不清楚。

日本九州大学的研究人员制作了患有特应性皮炎的模型鼠,并将其与那些经基因检测为健康的野生鼠进行对比,结果发现,有一种蛋白质“EPAS1”仅存在于患有严重特应性皮炎的老鼠的免疫细胞内,而正常老鼠的免疫细胞内则没有。此外,通过基因操作,使免疫细胞内的EPAS1发生加强或减少时,会导致IL-31发生相应的增减。另外,对特应性皮炎患者提供的血液进行化验后,发现其中的IL-31是常人的5倍;对试管中EPAS1的作用进行人为抑止后,发现IL-31量降为原来的1/10。通过上述实验,确定了EPAS1蛋白质对特应性皮炎的关键作用。

以往对特应性皮炎都是对免疫系统注入免疫抑制剂,副作用很大。研究人员希望能够以此发现为契机,找到仅对EPAS1起作用,对身体无副作用的药物。

这一成果发表于英国科学《Nature Communications》1月9日电子版上。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2086944, encodeId=fd98208694401, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 09 20:25:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881663, encodeId=c28f188166382, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 04 11:25:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177126, encodeId=a2121e71269e, content=特异性皮炎用他克莫司,效果很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9c2002147, createdName=1e1cd78dm87(暂无匿称), createdTime=Mon Feb 20 12:08:37 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294301, encodeId=176f129430101, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Feb 18 01:25:00 CST 2017, time=2017-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442560, encodeId=3b65144256008, content=<a href='/topic/show?id=7aa28e73211' target=_blank style='color:#2F92EE;'>#药物开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87732, encryptionId=7aa28e73211, topicName=药物开发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92874938033, createdName=ms1774076774505970, createdTime=Sat Feb 18 01:25:00 CST 2017, time=2017-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573394, encodeId=72af15e339404, content=<a href='/topic/show?id=28f4125430b' target=_blank style='color:#2F92EE;'>#Nature Communications#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12543, encryptionId=28f4125430b, topicName=Nature Communications)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bea15872676, createdName=qindq, createdTime=Sat Feb 18 01:25:00 CST 2017, time=2017-02-18, status=1, ipAttribution=)]
    2017-09-09 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2086944, encodeId=fd98208694401, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 09 20:25:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881663, encodeId=c28f188166382, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 04 11:25:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177126, encodeId=a2121e71269e, content=特异性皮炎用他克莫司,效果很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9c2002147, createdName=1e1cd78dm87(暂无匿称), createdTime=Mon Feb 20 12:08:37 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294301, encodeId=176f129430101, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Feb 18 01:25:00 CST 2017, time=2017-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442560, encodeId=3b65144256008, content=<a href='/topic/show?id=7aa28e73211' target=_blank style='color:#2F92EE;'>#药物开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87732, encryptionId=7aa28e73211, topicName=药物开发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92874938033, createdName=ms1774076774505970, createdTime=Sat Feb 18 01:25:00 CST 2017, time=2017-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573394, encodeId=72af15e339404, content=<a href='/topic/show?id=28f4125430b' target=_blank style='color:#2F92EE;'>#Nature Communications#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12543, encryptionId=28f4125430b, topicName=Nature Communications)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bea15872676, createdName=qindq, createdTime=Sat Feb 18 01:25:00 CST 2017, time=2017-02-18, status=1, ipAttribution=)]
    2017-05-04 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2086944, encodeId=fd98208694401, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 09 20:25:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881663, encodeId=c28f188166382, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 04 11:25:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177126, encodeId=a2121e71269e, content=特异性皮炎用他克莫司,效果很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9c2002147, createdName=1e1cd78dm87(暂无匿称), createdTime=Mon Feb 20 12:08:37 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294301, encodeId=176f129430101, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Feb 18 01:25:00 CST 2017, time=2017-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442560, encodeId=3b65144256008, content=<a href='/topic/show?id=7aa28e73211' target=_blank style='color:#2F92EE;'>#药物开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87732, encryptionId=7aa28e73211, topicName=药物开发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92874938033, createdName=ms1774076774505970, createdTime=Sat Feb 18 01:25:00 CST 2017, time=2017-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573394, encodeId=72af15e339404, content=<a href='/topic/show?id=28f4125430b' target=_blank style='color:#2F92EE;'>#Nature Communications#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12543, encryptionId=28f4125430b, topicName=Nature Communications)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bea15872676, createdName=qindq, createdTime=Sat Feb 18 01:25:00 CST 2017, time=2017-02-18, status=1, ipAttribution=)]
    2017-02-20 1e1cd78dm87(暂无匿称)

    特异性皮炎用他克莫司,效果很好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2086944, encodeId=fd98208694401, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 09 20:25:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881663, encodeId=c28f188166382, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 04 11:25:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177126, encodeId=a2121e71269e, content=特异性皮炎用他克莫司,效果很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9c2002147, createdName=1e1cd78dm87(暂无匿称), createdTime=Mon Feb 20 12:08:37 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294301, encodeId=176f129430101, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Feb 18 01:25:00 CST 2017, time=2017-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442560, encodeId=3b65144256008, content=<a href='/topic/show?id=7aa28e73211' target=_blank style='color:#2F92EE;'>#药物开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87732, encryptionId=7aa28e73211, topicName=药物开发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92874938033, createdName=ms1774076774505970, createdTime=Sat Feb 18 01:25:00 CST 2017, time=2017-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573394, encodeId=72af15e339404, content=<a href='/topic/show?id=28f4125430b' target=_blank style='color:#2F92EE;'>#Nature Communications#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12543, encryptionId=28f4125430b, topicName=Nature Communications)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bea15872676, createdName=qindq, createdTime=Sat Feb 18 01:25:00 CST 2017, time=2017-02-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2086944, encodeId=fd98208694401, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 09 20:25:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881663, encodeId=c28f188166382, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 04 11:25:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177126, encodeId=a2121e71269e, content=特异性皮炎用他克莫司,效果很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9c2002147, createdName=1e1cd78dm87(暂无匿称), createdTime=Mon Feb 20 12:08:37 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294301, encodeId=176f129430101, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Feb 18 01:25:00 CST 2017, time=2017-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442560, encodeId=3b65144256008, content=<a href='/topic/show?id=7aa28e73211' target=_blank style='color:#2F92EE;'>#药物开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87732, encryptionId=7aa28e73211, topicName=药物开发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92874938033, createdName=ms1774076774505970, createdTime=Sat Feb 18 01:25:00 CST 2017, time=2017-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573394, encodeId=72af15e339404, content=<a href='/topic/show?id=28f4125430b' target=_blank style='color:#2F92EE;'>#Nature Communications#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12543, encryptionId=28f4125430b, topicName=Nature Communications)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bea15872676, createdName=qindq, createdTime=Sat Feb 18 01:25:00 CST 2017, time=2017-02-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2086944, encodeId=fd98208694401, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 09 20:25:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881663, encodeId=c28f188166382, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 04 11:25:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177126, encodeId=a2121e71269e, content=特异性皮炎用他克莫司,效果很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9c2002147, createdName=1e1cd78dm87(暂无匿称), createdTime=Mon Feb 20 12:08:37 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294301, encodeId=176f129430101, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Feb 18 01:25:00 CST 2017, time=2017-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442560, encodeId=3b65144256008, content=<a href='/topic/show?id=7aa28e73211' target=_blank style='color:#2F92EE;'>#药物开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87732, encryptionId=7aa28e73211, topicName=药物开发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92874938033, createdName=ms1774076774505970, createdTime=Sat Feb 18 01:25:00 CST 2017, time=2017-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573394, encodeId=72af15e339404, content=<a href='/topic/show?id=28f4125430b' target=_blank style='color:#2F92EE;'>#Nature Communications#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12543, encryptionId=28f4125430b, topicName=Nature Communications)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bea15872676, createdName=qindq, createdTime=Sat Feb 18 01:25:00 CST 2017, time=2017-02-18, status=1, ipAttribution=)]